Literature DB >> 18077480

Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters.

A Minneboo1, B Jasperse, F Barkhof, B M J Uitdehaag, D L Knol, V de Groot, C H Polman, J A Castelijns.   

Abstract

OBJECTIVE: Magnetic resonance imaging (MRI) and clinical parameters are associated with disease progression in multiple sclerosis (MS). The aim of this study was to investigate whether adding MRI parameters to a model with only clinical parameters could improve these associations.
METHODS: 89 patients (55 women) with recently diagnosed MS had clinical and MRI evaluation at baseline (time of diagnosis) and at follow-up after 2.2 years. Detailed clinical data were available, including disease type (relapse-onset or progressive-onset) and disability, as measured by the Expanded Disability Status Scale (EDSS). MRI parameters included Normalised Brain Volume (NBV) at baseline, percentage brain volume change (PBVC/year), T2- and T1-lesion loads and spinal cord abnormalities. Progression of disability (increase in EDSS of at least 1 point at follow-up) was the main outcome measure. For a model containing only clinical parameters, the added value of MRI parameters was tested using logistic regression.
RESULTS: PBVC/year and lesion loads at follow-up were significantly higher in the group with progression. Adding PBVC/year to a clinical model improved the model, indicating that MRI parameters added independent information (p<0.001).
CONCLUSION: The rate of cerebral atrophy conveys added information for the progression of disability in patients with early MS, suggesting that clinical disability is determined by neurodegenerative changes as depicted by MRI.

Entities:  

Mesh:

Year:  2007        PMID: 18077480     DOI: 10.1136/jnnp.2007.124123

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  18 in total

Review 1.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

Review 2.  Clinical relevance of brain volume measures in multiple sclerosis.

Authors:  Nicola De Stefano; Laura Airas; Nikolaos Grigoriadis; Heinrich P Mattle; Jonathan O'Riordan; Celia Oreja-Guevara; Finn Sellebjerg; Bruno Stankoff; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

3.  Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis.

Authors:  E Ghione; N Bergsland; M G Dwyer; J Hagemeier; D Jakimovski; D P Ramasamy; D Hojnacki; A A Lizarraga; C Kolb; S Eckert; B Weinstock-Guttman; R Zivadinov
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-06       Impact factor: 3.825

4.  Computational classifiers for predicting the short-term course of Multiple sclerosis.

Authors:  Bartolome Bejarano; Mariangela Bianco; Dolores Gonzalez-Moron; Jorge Sepulcre; Joaquin Goñi; Juan Arcocha; Oscar Soto; Ubaldo Del Carro; Giancarlo Comi; Letizia Leocani; Pablo Villoslada
Journal:  BMC Neurol       Date:  2011-06-07       Impact factor: 2.474

5.  Accurate GM atrophy quantification in MS using lesion-filling with co-registered 2D lesion masks.

Authors:  V Popescu; N C G Ran; F Barkhof; D T Chard; C A Wheeler-Kingshott; H Vrenken
Journal:  Neuroimage Clin       Date:  2014-01-18       Impact factor: 4.881

Review 6.  A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives.

Authors:  Emanuele D'Amico; Francesco Patti; Aurora Zanghì; Mario Zappia
Journal:  Int J Mol Sci       Date:  2016-10-17       Impact factor: 5.923

7.  Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis.

Authors:  Nicola De Stefano; Maria Laura Stromillo; Antonio Giorgio; Maria Letizia Bartolozzi; Marco Battaglini; Mariella Baldini; Emilio Portaccio; Maria Pia Amato; Maria Pia Sormani
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-04-22       Impact factor: 10.154

8.  A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis.

Authors:  Raed Alroughani; Dirk Deleu; Khalid El Salem; Jasem Al-Hashel; K John Alexander; Mohamed Assem Abdelrazek; Adel Aljishi; Jaber Alkhaboori; Faisal Al Azri; Nahida Al Zadjali; Majed Hbahbih; Tag Eldin Sokrab; Mohamed Said; Àlex Rovira
Journal:  BMC Neurol       Date:  2016-11-24       Impact factor: 2.474

Review 9.  Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.

Authors:  Alberto Gajofatto; Massimiliano Calabrese; Maria Donata Benedetti; Salvatore Monaco
Journal:  Dis Markers       Date:  2013-11-10       Impact factor: 3.434

Review 10.  Optimizing treatment success in multiple sclerosis.

Authors:  Tjalf Ziemssen; Tobias Derfuss; Nicola de Stefano; Gavin Giovannoni; Filipe Palavra; Davorka Tomic; Tim Vollmer; Sven Schippling
Journal:  J Neurol       Date:  2015-12-24       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.